➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
Moodys
Merck
Express Scripts
Johnson and Johnson

Last Updated: May 30, 2020

DrugPatentWatch Database Preview

Patent: 9,527,857

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,527,857
Title:HSPC-sparing treatments for RB-positive abnormal cellular proliferation
Abstract: This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, improved treatment of select RB-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as highly selective and, in certain embodiments, short, transiently-acting cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
Inventor(s): Strum; Jay Copeland (Hillsborough, NC), Bisi; John Emerson (Apex, NC), Roberts; Patrick Joseph (Durham, NC), Tavares; Francis Xavier (Durham, NC)
Assignee: GI Therapeutics, Inc. (Research Triangle Park, NC)
Application Number:14/214,048
Patent Claims:see list of patent claims

Details for Patent 9,527,857

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial GI Therapeutics, Inc. (Research Triangle Park, NC) 2033-03-15 RX search
Genentech KADCYLA ado-trastuzumab emtansine VIAL; SINGLE-USE 125427 002 2013-02-22   Start Trial GI Therapeutics, Inc. (Research Triangle Park, NC) 2033-03-15 RX search
Genentech KADCYLA ado-trastuzumab emtansine VIAL; SINGLE-USE 125427 001 2013-02-22   Start Trial GI Therapeutics, Inc. (Research Triangle Park, NC) 2033-03-15 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial GI Therapeutics, Inc. (Research Triangle Park, NC) 2033-03-15 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,527,857

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Dow
AstraZeneca
Baxter
Merck
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.